香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：2005） 截至二零二三年十二月三十一日止年度 全年業績公佈 主席報告 本人謹代表石四藥集團有限公司（本公司）董事局（「董事局」），呈報本公司及其附屬公司（簡 稱「集團」）截至二零二三年十二月三十一日止年度的全年業績。 一、業績及派息 2023年，面對錯綜複雜的外部環境和國內醫藥行業競爭日益激烈等多重因素的影響， 集團通過提升新產品開發效率、調整產銷結構、拓展銷售渠道等舉措，加大優勢製劑、 重點製劑、大宗原料藥和藥包材的市場份額和規模，集團經營整體穩中向好，推動 高質量發展再上新台階。 2023年全年實現銷售收入以人民幣計約58.24億元，同比增長約4.9%，但由於人民幣 兌港元較去年平均貶值約4.3%，以港元計，全年銷售收入約64.63億港元，同比增長 約0.5%，同期毛利率56.0%，同比上漲0.6個百分點；實現淨利潤約13.19億港元，同比 增長約17. ...

Financial Performance - Sales revenue for the first half of 2023 reached approximately RMB 2.962 billion, a year-on-year increase of 4.7%, but due to the depreciation of RMB against HKD by approximately 6.5%, the sales revenue in HKD terms was approximately HKD 3.333 billion, a year-on-year decrease of 2.1%[3] - Net profit for the first half of 2023 was approximately HKD 639 million, a year-on-year increase of 12%[3] - Revenue for the six months ended June 30, 2023, was HKD 3,333.16 million, a decrease of 2.1% compared to HKD 3,404.51 million in the same period last year[68] - Gross profit for the six months ended June 30, 2023, was HKD 1,944.75 million, a slight increase of 0.3% compared to HKD 1,939.45 million in the same period last year[68] - Operating profit for the six months ended June 30, 2023, was HKD 792.48 million, an increase of 4.8% compared to HKD 756.32 million in the same period last year[68] - Net profit attributable to equity holders of the company for the six months ended June 30, 2023, was HKD 638.61 million, an increase of 12.0% compared to HKD 570.06 million in the same period last year[70] - Basic earnings per share for the six months ended June 30, 2023, was HKD 0.2149, an increase of 12.8% compared to HKD 0.1906 in the same period last year[70] - Total assets as of June 30, 2023, were HKD 8,626.78 million, an increase of 4.1% compared to HKD 8,288.63 million as of December 31, 2022[71] - Net current assets as of June 30, 2023, were HKD 2,341.34 million, an increase of 6.1% compared to HKD 2,206.57 million as of December 31, 2022[71] - Total assets increased to HKD 6,681,527 thousand as of June 30, 2023, compared to HKD 6,545,824 thousand at the end of 2022[72] - Non-current liabilities rose to HKD 1,945,248 thousand, up from HKD 1,742,802 thousand at the end of 2022[72] - Operating cash flow for the six months ended June 30, 2023, was HKD 661,515 thousand, a significant increase from HKD 362,146 thousand in the same period last year[76] - Net cash generated from operating activities was HKD 463,601 thousand, compared to HKD 193,380 thousand in the previous year[76] - Investment activities used HKD 265,381 thousand in cash, slightly higher than HKD 245,941 thousand in the same period last year[76] - Cash and cash equivalents at the end of June 2023 stood at HKD 1,789,616 thousand, up from HKD 1,625,224 thousand at the end of June 2022[78] - Dividends paid to shareholders amounted to HKD 237,604 thousand, compared to HKD 209,073 thousand in the previous year[78] - The company repurchased and canceled shares worth HKD 13,672 thousand during the period[78] - Borrowings received during the period totaled HKD 688,129 thousand, down from HKD 1,808,986 thousand in the previous year[78] - The company's equity attributable to shareholders increased to HKD 6,350,612 thousand, up from HKD 6,213,600 thousand at the end of 2022[72] - Revenue from sales of pharmaceuticals decreased to HKD 3,225,011 thousand in 2023 from HKD 3,294,478 thousand in 2022, a decline of approximately 2.1%[85] - Revenue from medical materials increased slightly to HKD 89,097 thousand in 2023 from HKD 87,850 thousand in 2022, a growth of approximately 1.4%[85] - Total customer contract revenue under HKFRS 15 decreased to HKD 3,333,157 thousand in 2023 from HKD 3,404,396 thousand in 2022, a decline of approximately 2.1%[85] - Revenue from China (domestic) increased to HKD 3,013,522 thousand in 2023 from HKD 2,850,800 thousand in 2022, a growth of approximately 5.7%[85] - Revenue from other countries decreased significantly to HKD 319,635 thousand in 2023 from HKD 553,713 thousand in 2022, a decline of approximately 42.3%[85] - Operating profit for the intravenous infusion and other segment was HKD 806,104 thousand in 2023, compared to HKD 763,408 thousand in 2022, an increase of approximately 5.6%[87][91] - Operating profit for the medical materials segment was HKD 10,484 thousand in 2023, compared to HKD 10,316 thousand in 2022, a slight increase of approximately 1.6%[87][91] - Total profit before tax for the reportable segments was HKD 770,699 thousand in 2023, compared to HKD 749,219 thousand in 2022, an increase of approximately 2.9%[87][91] - Total profit for the reportable segments after tax was HKD 649,505 thousand in 2023, compared to HKD 611,476 thousand in 2022, an increase of approximately 6.2%[87][90] - Total assets for the reportable segments were HKD 10,966,512 thousand as of December 31, 2022, with the intravenous infusion and other segment accounting for HKD 10,355,222 thousand[92] - Total reportable segment assets amounted to 11,331,939 thousand HKD, with intravenous infusion and others contributing 10,685,003 thousand HKD[93] - Total reportable segment liabilities were 4,650,412 thousand HKD, with intravenous infusion and others accounting for 3,350,970 thousand HKD[93] - Net financial costs increased to 35,958 thousand HKD in 2023 from 13,187 thousand HKD in 2022[95] - Employee costs rose to 341,362 thousand HKD in 2023, up from 299,452 thousand HKD in 2022[96] - R&D expenses increased to 243,021 thousand HKD in 2023, with 104,273 thousand HKD capitalized as intangible assets[97] - Inventory costs decreased to 1,384,100 thousand HKD in 2023 from 1,474,961 thousand HKD in 2022[97] - Current tax expense for corporate income tax in China was 117,916 thousand HKD in 2023, down from 137,942 thousand HKD in 2022[98] - Basic earnings per share increased to 638,611 thousand HKD in 2023 from 570,056 thousand HKD in 2022[100] - Diluted earnings per share were calculated based on 2,985,285 thousand weighted average shares in 2023[101] - The weighted average number of ordinary shares (diluted) was 2,985,285 thousand in 2023, up from 2,990,288 thousand in 2022[102] - The company acquired property, plant, and equipment with a cost of HKD 442,789,000 and intangible assets with a cost of HKD 104,552,000 during the six months ended June 30, 2023[103] - The company sold plant and equipment with a book value of HKD 4,416,000, generating a gain of HKD 399,000 during the six months ended June 30, 2023[103] - The company's investment in Chenxin Pharmaceutical, an associate, was valued at HKD 399,200,000 as of June 30, 2023, representing a 6.10% equity interest[104][105] - The company received dividends of HKD 10,052,000 from Chenxin Pharmaceutical during the six months ended June 30, 2023[105] - The company's inventory increased to HKD 1,000,583,000 as of June 30, 2023, compared to HKD 810,656,000 as of December 31, 2022[106] - The company's trade receivables and bills decreased to HKD 1,990,902,000 as of June 30, 2023, compared to HKD 2,112,680,000 as of December 31, 2022[108] - The company's bank acceptance bills receivable decreased to HKD 139,075,000 as of June 30, 2023, compared to HKD 191,746,000 as of December 31, 2022[108] - The company's total borrowings increased to HKD 3,379,969,000 as of June 30, 2023, compared to HKD 3,207,648,000 as of December 31, 2022[110] - The company's trade payables and bills increased to HKD 494,157,000 as of June 30, 2023, compared to HKD 361,063,000 as of December 31, 2022[113] - The interim dividend for 2023 is HK$0.07 per share, totaling HK$207,903 thousand, compared to HK$0.06 per share and HK$179,043 thousand in 2022[114] - The proposed final dividend for 2023 is HK$0.08 per share, totaling HK$237,604 thousand, compared to HK$0.07 per share and HK$209,073 thousand in 2022[115] - The company repurchased 2,640,000 shares in the first half of 2023, with a total cost of HK$13,672 thousand, compared to 9,938,000 shares and HK$36,193 thousand in 2022[116] - The fair value of financial assets measured at fair value through other comprehensive income (FVTOCI) was HK$139,075 thousand as of June 30, 2023, classified under Level 2[121] - The fair value of financial assets measured at FVTOCI was HK$191,746 thousand as of December 31, 2022, classified under Level 2[122] - The company's capital commitments as of June 30, 2023, were HK$641,902 thousand, compared to HK$524,849 thousand as of December 31, 2022[124] - Sales to Kelun Group in the first half of 2023 amounted to HK$35,014 thousand, compared to HK$26,198 thousand in 2022[128] - Purchases from Kelun Group in the first half of 2023 amounted to HK$148,519 thousand, compared to HK$91,845 thousand in 2022[128] - The trustee purchased 3,300,000 shares under the restricted share award plan after the reporting period, with a total cost of HK$14,933 thousand[129] Product Sales and Market Performance - Large infusion products achieved a cumulative sales volume of approximately 936 million bottles (bags), with sales revenue of HKD 2.069 billion, a year-on-year increase of 24.1% and 12.8% respectively[6] - Therapeutic infusion products achieved sales revenue of HKD 566 million, a year-on-year increase of 24.7%[6] - Ampoule product sales volume reached approximately 131 million units, a year-on-year increase of 92%[7] - Hydrobromide injection sales reached approximately HKD 180 million, a year-on-year increase of 4.6 times[7] - Ambroxol hydrochloride injection sales reached approximately HKD 14.67 million, a year-on-year increase of 98%[7] - Sales of Bidol capsules reached 22.56 million units, a year-on-year increase of approximately 302%[8] - Sales of Rosuvastatin Calcium Tablets reached 29.3 million units, a year-on-year increase of approximately 60%[8] - Sales of Azithromycin Dispersible Tablets reached 34.79 million units, a year-on-year increase of approximately 43%[8] - Export sales of infusion products reached 51.08 million bottles (bags), a year-on-year increase of approximately 17%, with export sales revenue of 80.08 million HKD, a year-on-year increase of approximately 25%[9] - Revenue from intravenous infusion products increased by 12.8% to HKD 2,069,115,000, driven by strong post-pandemic demand in China[21] - Non-PVC soft bag and upright soft bag infusion revenue increased by 16.3% to HKD 1,526,497,000, accounting for 73.8% of intravenous infusion revenue[21] - Revenue from oral formulations surged by 68.4% to HKD 244,391,000, supported by new products such as antiviral drug Abidol capsules[21] - Revenue from active pharmaceutical ingredients (API) decreased by 41.6% to HKD 453,626,000 due to weak market demand and price declines[21] - Revenue from ampoule injections declined by 11.2% to HKD 453,398,000, influenced by changes in product mix and centralized procurement sales[21] - Medical materials revenue slightly decreased by 0.5% to HKD 90,067,000[22] Research and Development - The company successfully bid for 5 products with 7 specifications in the 8th national drug centralized procurement, bringing the total number of products selected for national drug centralized procurement to 13 varieties with 18 specifications[5] - New products such as Lacosamide Injection, Peritoneal Dialysis Solution, and Terbutaline Sulfate Injection have gained market access in 30, 27, and 23 provinces respectively[5] - The company obtained 34 production approvals, including 8 for APIs and 26 for formulations, with several products being the first or second in China to receive approvals[11] - The company's innovative drug NP-01 for anti-tumor treatment showed positive progress in Phase I clinical trials, with expected completion of Phase I tolerance study by November 2023[12] - The company has 51 products with 67 specifications that have passed or are deemed to have passed consistency evaluations, enhancing market competitiveness[12] - The company applied for 49 patents and was granted 26, including 24 invention patents, bringing the total number of valid patents to 254, with 128 being invention patents[12] - R&D costs increased by 11.5% to HKD 138,748,000 in the first half of 2023, reflecting the company's focus on new product development in finished drugs, APIs, and medical materials[26][28] - Research and development costs for the six months ended June 30, 2023, were HKD 138.75 million, an increase of 11.5% compared to HKD 124.43 million in the same period last year[68] Corporate Governance and Shareholder Information - The company declared an interim dividend of HKD 0.07 per share, a year-on-year increase of 16.7%[3] - The company plans to focus on expanding the market share of high-value-added products and optimizing the production and sales structure in the second half of 2023[14] - The company is actively promoting the spin-off and listing of Bosheng Medical Materials on the Beijing Stock Exchange and seeking M&A opportunities in the pharmaceutical industry[15] - The company continues to focus on producing high-quality intravenous infusion products and launching new products in ampoule injections, APIs, oral formulations, and medical materials[22] - The company has established a dedicated team to handle centralized procurement and other forms of drug bidding to mitigate risks[17] - The company has obtained more product registrations that have passed or are deemed to have passed consistency evaluations, qualifying them for centralized procurement[17] - The company emphasizes environmental sustainability and green manufacturing, adhering to GMP standards and implementing low-energy and low-pollution measures[18] - Sales cost decreased by 5.2% to HKD 1,388,406,000 from HKD 1,465,066,000 in the first half of 2023, with direct materials, direct labor, and other costs accounting for 54.8%, 14.4%, and 30.8% of total sales cost respectively[23] - Gross profit margin increased by 1.3 percentage points to 58.3% in the first half of 2023, driven by a higher proportion of revenue from higher-margin finished drugs[24] - Other net income increased to HKD 45,301,000 in the first half of 2023, primarily due to government grants[25] - Operating profit increased by 4.8% to HKD 792,484,000 in the first half of 2023, with operating profit margin improving to 23.8% from 22.2%[29] - Net finance costs increased by 172.7% to HKD 35,958,000 in the first half of 2023 due to higher average bank borrowing rates[30] - Income tax expense decreased by 12.0% to HKD 121,194,000 in the first half of 2023, benefiting from a preferential tax rate of 15% for high-tech enterprises[31] - Profit attributable to equity holders increased by 12.0% to HKD 638,611,000 in the first half of 2023, with net profit margin rising to 19.2% from 16.7%[32] - Cash and cash equivalents increased to HKD 1,789,616,000 as of June 30, 2023, with bank borrowings slightly rising to HKD 3,379,969,000[34] - Capital-to-debt ratio remained stable at 20.1% as of June 30, 2023, with a current ratio improving to 1.87 from 1.82[34] - Total employee count increased to 5,300 as of June 30, 2023, up from 4,800 in the same period last year, reflecting a 10.4% growth[35] - Total employee compensation costs for the first six

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2005) （於開曼群島註冊成立之有限公司） （股份代號：2005） 截至二零二三年六月三十日止六個月 中期業績公佈 主席報告 本人謹代表石四藥集團有限公司（「本公司」）董事局（「董事局」），呈報本公司及其附屬公司 （簡稱「集團」）截至二零二三年六月三十日止六個月的未經審核中期業績。 一、業績及派息 2023年上半年，面對國內外醫藥市場的嚴峻挑戰，集團銳意進取、搶抓機遇、迎難而 上，通過加快研發創新、整合市場資源、積極挖掘潛能等一系列經營舉措，持續保持了企 業穩定健康發展的良好態勢。 今年上半年實現銷售收入以人民幣計約29.62億元，同比增長約4.7%，但由於人民幣兌港 元較去年同期貶值約6.5%，以港元而言，今年上半年銷售收入約33.33億港元，同比下降 2. ...

Financial Performance - In 2022, the company achieved a sales revenue of HKD 6.434 billion, representing a year-on-year growth of approximately 20%[6] - The net profit for 2022 reached HKD 1.123 billion, reflecting a year-on-year increase of approximately 43%[6] - The company distributed a final dividend of HKD 0.08 per share, with a total annual dividend of HKD 0.14 per share, marking a year-on-year increase of approximately 17%[6] - The company's revenue for the year ended December 31, 2022, increased to HKD 6,434,025,000, representing a year-on-year growth of 20.1% from HKD 5,356,763,000 in 2021[23] - The revenue from intravenous infusion products was HKD 3,510,342,000, a 6.2% increase from HKD 3,304,365,000 in the previous year, contributing 69.4% to total intravenous infusion revenue[23] - The company reported a gross profit of HKD 3,567,586,000, which is a 12.5% increase from HKD 3,170,246,000 in the prior year[153] - Operating profit rose by 44.1% to HKD 1,423,713,000 for the year ended December 31, 2022, with an operating margin increasing from 18.4% in 2021 to 22.1%[30] - Profit attributable to equity holders increased by 42.9% to HKD 1,122,837,000 for the year ended December 31, 2022, with a net profit margin rising from 14.7% in 2021 to 17.5%[32] Sales and Product Performance - The company sold 1.58 billion bottles (bags) of large-volume injections, achieving a year-on-year growth of approximately 16%[7] - Sales of peritoneal dialysis solution reached 3.79 million bags, a year-on-year increase of 77%[7] - The sales volume of hydrochloride ambroxol sodium injection reached approximately 15.1 million bottles (bags), a year-on-year increase of approximately 1,694%[7] - The sales revenue from solid preparations reached HKD 346 million, representing a year-on-year growth of approximately 62%[7] - The sales of ampoule products reached approximately 160 million units, with a year-on-year growth of approximately 49%[7] - The sales revenue of the raw material pharmaceutical business reached HKD 1.36 billion, a year-on-year increase of approximately 155%[8] - Caffeine sales amounted to approximately 5,000 tons, representing a year-on-year growth of about 81%[8] Research and Development - The group obtained 37 various product approvals, including four first-in-class products in China[10] - The innovative drug NP-01 for cancer treatment showed positive results in Phase I clinical trials, with plans for Phase II trials in July 2023[11] - The group has applied for a total of 361 patents, with 106 granted in China and 6 internationally[11] - R&D costs increased by 4.5% to HKD 259,104,000 for the year ended December 31, 2022, from HKD 247,992,000 in 2021, driven by accelerated development of new products[29] Corporate Governance - The company is led by Chairman and CEO Mr. Qu Jiguang, who has over 30 years of experience in the pharmaceutical industry[38] - The board includes independent directors with significant industry experience, such as Mr. Wang Yibing, who has over 30 years in pharmaceutical research and regulation[41] - The company has maintained compliance with the corporate governance code throughout the year ending December 31, 2022, except for the aforementioned deviation[44] - The board of directors consists of four executive directors and four independent non-executive directors, with the chairman also serving as the CEO, which is a deviation from the corporate governance code[44] Environmental Sustainability - The company emphasizes the importance of environmental sustainability and green manufacturing, adhering to GMP standards and implementing low-energy consumption measures[19] - The company recognizes the importance of sustainable development and green manufacturing, integrating ESG considerations into daily operations[74] - In 2022, the total greenhouse gas emissions amounted to 248,480 tons, an increase from 221,861 tons in 2021, while the greenhouse gas emissions density improved to 9,230 tons per million products from 12,850 tons[85] - The company has established three wastewater treatment plants to enhance treatment capacity, ensuring compliance with industrial zone discharge standards[86] Employee Relations - Total number of employees increased from 4,772 in 2021 to 5,004 in 2022, representing a growth of 4.8%[96] - Employee turnover rate decreased from 21.5% in 2021 to 17.0% in 2022, indicating improved employee retention[97] - The company maintained a zero fatality rate due to work-related incidents over the past three years[102] - The percentage of employees receiving training on occupational health and safety was 97.6% for males and 92.5% for females in 2022[99] Shareholder Value and Dividends - The company aims to enhance its net asset value and earnings per share through share repurchases under suitable market conditions[112] - The company reported a total dividend of HKD 0.14 per share for the year ended December 31, 2022, an increase from HKD 0.12 per share in the previous year[110] - The mid-term dividend declared was HKD 0.06 per share, up from HKD 0.05 per share in the previous year, while the proposed final dividend is HKD 0.08 per share, compared to HKD 0.07 per share last year[110] Financial Management - The total accounts receivable amounted to HKD 1,935 million, with an expected credit loss of HKD 14 million, representing approximately 17.5% of total assets as of December 31, 2022[149] - The company recognizes revenue when control of goods transfers to customers, which occurs upon delivery or acceptance by the customer[148] - The group confirms impairment gains or losses for all financial instruments and adjusts their carrying amounts accordingly[199] Strategic Initiatives - The company is actively pursuing the spin-off listing of its raw material drug business and seeking acquisition opportunities in the pharmaceutical industry to strengthen its market position[15] - The company plans to continue focusing on high-quality intravenous infusion products and expand its market for raw materials, ampoule injections, oral formulations, and new medical materials[24] - The company aims to establish two new upright soft bag production lines, adding an annual production capacity of 600 million bags, utilizing advanced technologies for smart manufacturing and digital transformation[14]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部份內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：2005） 截至二零二二年十二月三十一日止年度 全年業績公佈 主席報告 本人謹代表石四藥集團有限公司（本公司）董事局（「董事局」），呈報本公司及其附屬公司（簡 稱「集團」）截至二零二二年十二月三十一日止年度的年報。 一、業績及派息 2022年，針對新冠疫情反復波動和國家藥品集採改革深層遞進，集團聚焦國內、國 際市場需求，積極克服困難，高效統籌市場資源配置，加大優勢製劑、重點製劑品 種及大宗原料藥和藥包材的市場拓展，不斷優化產品結構，突出特色新品營銷，市 場份額、銷售規模取得新進展，整體經營持續穩定向好，集團銷售收入再創歷史新高。 2022年全年實現銷售收入64.34億港元，同比增長約20%，同期毛利率55.4%，同比下 降3.8個百分點，毛利率下降主要原因是原料藥佔收入比例的增加，但也帶來銷售費 用的下降。實現淨利潤11.23億港元，同比增長約43%。 — 1 ...